Unicycive Therapeutics Inc (NASDAQ:UNCY) does about 2.66M shares in volume on a normal day but saw 5049905 shares change hands in the recent trading day. The company now has a market cap of 90.99M USD. Its current market price is $0.75, marking an increase of 10.70% compared to the previous close of $0.68. The 52 week high reached by this stock is $1.10 whilst the lowest price level in 52 weeks is $0.20.
The consensus objective for the share price is $6.50, suggesting that the stock has a potential upside of 88.46% over the period.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 21, 2025 when Guggenheim initiated the stock to “Buy” and issued a price target of $6.
The current price level is 15.05%, 22.12%, and 32.97% away from its SMA20, SMA50, and SMA200 respectively, with the UNCY price moving below the 50-day SMA on current market day. Unicycive Therapeutics Inc (UNCY) stock is down -16.19% over the week and 37.00% over the past month. Its price is -5.02% year-to-date and 14.22% over the past year.
To reach the target analysts have set, the stock logically needs to grow 88.46 percent from here.
The company has a return on investment of -195.79% and return on equity of -2355.27%. The forward price to earnings ratio is 0.47. The beta has a value of 2.00. Price to book ratio is 8.01.
